Influence of the postoperative residual tumor on the outcome of therapy with pazopanib in ovarian cancer (OC): A subgroup analysis of an international intergroup trial (AGO-OVAR16)

被引：0

作者：

Gropp-Meier, M. ^{[1
]}

Schmalfeld, B. ^{[2
]}

Belau, A. ^{[3
]}

Rau, J. ^{[4
]}

Richter, B. ^{[5
]}

Emons, G. ^{[6
]}

Hillemanns, P. ^{[7
]}

Lueck, H. -J. ^{[8
]}

Burges, A. ^{[9
]}

Fehm, T. ^{[10
]}

Harter, P. ^{[11
]}

Wimberger, P. ^{[12
]}

Baumann, K. ^{[13
]}

Kurzeder, C. ^{[14
]}

Canzler, U. ^{[15
]}

Meier, W. ^{[16
]}

Hanker, L. C. ^{[17
]}

Mahner, S. ^{[18
]}

Kosse, J. ^{[19
]}

Sehouli, J. ^{[20
]}

Suetterlin, M. ^{[21
]}

Zorr, A. ^{[22
]}

du Bois, A. ^{[23
]}

机构：

[1] Krankenhaus St Elisabeth, Frauenklin, Ravensburg, Germany

[2] Tech Univ Munich, Klinikum Rechts Isar, Frauen & Poliklin, D-80290 Munich, Germany

[3] Ernst Moritz Arndt Univ Greifswald, Univ Klinikum Greifswald, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Greifswald, Germany

[4] KKS Marburg, Marburg, Germany

[5] Elblandkliniken Meissen Radebeul GmbH & Co KG, Frauenklin, Radebeul, Germany

[6] Univ Gottingen, D-37073 Gottingen, Germany

[7] Hannover Med Sch, Frauenklin, D-30623 Hannover, Germany

[8] Gynakol Onkol Praxis, Hannover, Germany

[9] Klinikum Univ, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Munich, Germany

[10] Univ Klinikum Tubingen, Univ Frauenklin, Tubingen, Germany

[11] HSK Dr Horst Schmidt Klin, Klin Gynakol & Gynakol Onkol, Wiesbaden, Germany

[12] Univ Klinikum Essen, Klin Frauenheilkunde & Geburtshilfe, Essen, Germany

[13] Univ Klinikum Giessen & Marburg GmbH Standort Mar, Klin Gynakol Gynakol Endokrinol & Onkol, Marburg, Germany

[14] Univ Ulm Klinikum, Univ Frauenklin, Ulm, Germany

[15] Univ Klinikum Carl Gustav Carus, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Dresden, Germany

[16] Evangel Krankenhaus, Frauenklin, Dusseldorf, Germany

[17] Klinikum JW Goethe Univ, Zentrum Frauenheilkunde & Geburtshilfe, Frankfurt, Germany

[18] Univ Klinikum Hamburg Eppendorf, Klin & Poliklin Gynakol, Hamburg, Germany

[19] Klinikum Offenbach GmbH, Klin Gynakol & Geburtshilfe, Offenbach, Germany

[20] Charite, Campus Virchow Klinikum, Frauenklin, Berlin, Germany

[21] Univ Klinikum Mannheim, Frauenklink, Mannheim, Germany

[22] Klinikum Lippe Detmold, Frauenklin Lippe, Lippe, Germany

[23] Klinikum Essen Mitte, Klin Gynakol Onkol, Essen, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：69 / 69

页数：1

共 19 条

[1] Results of an international Intregroup randomized phase III trial of pazopanib versus placebo (AGO-OVAR16). Subgroup Analysis of toxicity and clinical outcome in the Asian and Non-Asian population
Sehouli, J.
Harter, P.
Wimberger, P.
Rau, J.
Baumann, K.
Kurzeder, C.
Canzler, U.
Meier, W.
Hanker, L. C.
Mahner, S.
Krabisch, P.
Reiter, W. W.
Aminossadati, B.
du Bois, A.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 75 - 75
[2] Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study
Kim, Jae-Weon
Mahner, Sven
Wu, Ling-Ying
Shoji, Tadahiro
Kim, Byoung-Gie
Zhu, Jian-Qing
Takano, Tadao
Park, Sang-Yoon
Kong, Bei-Hua
Wu, Qiang
Wang, Kung-Liahng
Ngan, Hextan Y. S.
Liu, Ji-Hong
Wei, Li-Hui
Mitrica, Ionel
Zhang, Pingkuan
Crescenzo, Rocco
Wang, Qiong
Cox, Charles J.
Harter, Philipp
du Bois, Andreas
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (01) : 2 - 10
[3] Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial
Fumet, Jean-David
Lardenois, Emilie
Ray-Coquard, Isabelle
Harter, Philipp
Joly, Florence
Canzler, Ulrich
Truntzer, Caroline
Tredan, Olivier
Liebrich, Clemens
Lortholary, Alain
Pissaloux, Daniel
Leary, Alexandra
Pfisterer, Jacobus
Eeckhoutte, Alexandre
Hilpert, Felix
Fabbro, Michel
Caux, Christophe
Alexandre, Jerome
Houlier, Aurelie
Sehouli, Jalid
Sohier, Emilie
Kimmig, Rainer
Dubois, Bertrand
Spaeth, Dominique
Treilleux, Isabelle
Frenel, Jean-Sebastien
Herwig, Uwe
Le Saux, Olivia
Bendriss-Vermare, Nathalie
du Bois, Andreas
CANCERS, 2022, 14 (05)
[4] BRCA1/2 MUTATIONS ASSOCIATED WITH PROGRESSION FREE SURVIVAL IN OVARIAN CANCER PATIENTS WHO RECEIVED PAZOPANIB OR PLACEBO IN THE AGO-OVAR16 STUDY
Harter, P.
Johnson, T.
Berton-Rigaud, D.
Park, S. Y.
Friedlander, M.
del Campo, J. M.
Shimada, M.
Forget, F.
Mirza, M. R.
Colombo, N.
Zamagni, C.
Chan, J. K.
Imhof, M.
Herzog, T. J.
O'Donnell, D.
King, K.
Stinnett, S.
Barrett, C.
Jobanputra, M.
Chun-Fang, X.
du Bois, A.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 40 - 41
[5] Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16).
Du Bois, Andreas
Floquet, Anne
Kim, Jae Weon
Rau, Joern
Maria Del Campo, Jose
Friedlander, Michael
Pignata, Sandro
Fujiwara, Keiichi
Vergote, Ignace
Colombo, Nicoletta
Mirza, Mansoor Raza
Monk, Bradley J.
Wimberger, Pauline
Ray-Coquard, Isabelle
Zang, Rongyu
Diaz-Padilla, Ivan
Baumann, Klaus H.
Kim, Jae Hoon
Harter, Philipp
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
[6] Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16).
Du Bois, Andreas
Floquet, Anne
Kim, Jae Weon
Rau, Joern
Del Campo, Jose Maria
Friedlander, Michael
Pignata, Sandro
Fujiwara, Kelichi
Vergote, Ignace
Colombo, Nicoletta
Mirza, Mansoor Raza
Monk, Bradley J.
Wimberger, Pauline
Ray-Coquard, Isabelle
Zang, Rongyu
Diaz-Padilla, Ivan
Baumann, Klaus H.
Kim, Jae Hoon
Harter, Philipp
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[7] Influence of Residual Tumor on Outcome in Ovarian Cancer Patients With FIGO Stage IV DiseaseAn Exploratory Analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group)
Pauline Wimberger
Michael Wehling
Nils Lehmann
Rainer Kimmig
Barbara Schmalfeldt
Alexander Burges
Philipp Harter
Jacobus Pfisterer
Andreas du Bois
Annals of Surgical Oncology, 2010, 17 (6) : 1642 - 1648
[8] Independent review of AGO-OVAR 12, a GCIG/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC).
Kristensen, Gunnar
Harter, Philipp
Tredan, Olivier
Sailer, Martin Oliver
Bamias, Aristotelis
Colombo, Nicoletta
Reinthaller, Alexander
Goffin, Frederic
Romeo, Margarita
Ottevanger, Petronella
Kimmig, Rainer
Malander, Susanne
Joly, Florence
De Gregorio, Nikolaus
Mirza, Mansoor Raza
Pfisterer, Jacobus
Minarik, Tomas
Pignata, Sandro
Merger, Michael
Du Bois, Andreas
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[9] Progression-free survival in patients in with advanced ovarian cancer defined by GCIG criteria vs. RECIST criteria: Analysis of the secondary endpoint of the AGO-Ovar16 trial
Mahner, S.
Jackisch, C.
Sehouli, J.
Rau, J.
Schmalfeldt, B.
Belau, A.
Richter, B.
Emons, G.
Park-Simon, T. -W.
Lueck, H. -J.
Burges, A.
Fehm, T.
Feisel-Schwickardi, G.
Clemens, M.
du Bois, A.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 68 - 69
[10] Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer
Vergote, I
du Bois, A.
Floquet, A.
Rau, J.
Kim, J-W
del Campo, J. M.
Friedlander, M.
Pignata, S.
Fujiwara, K.
Colombo, N.
Mirza, M. R.
Monk, B. J.
Tsibulak, I
Calvert, P. M.
Herzog, T. J.
Hanker, L. C.
Meunier, J.
Lee, J-Y
Bologna, A.
Carrasco-Alfonso, M. J.
Harter, P.
GYNECOLOGIC ONCOLOGY, 2019, 155 (02) : 186 - 191

← 1 2 →